Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates
NCT03507348Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Jul 2018
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Open-label trial of tocilizumab and rituximab in end stage renal disease (ESRD) (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Description of the results of the strategy of desensitization. Started Jul 2018; status: terminated.
02
Drugs
tocilizumabrituximab
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03507348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507348.